Abstract
Estraumustine phosphate (EMP), a cytotoxic drug used in the treatment of prostatic carcinoma, has been shown to exert cytotoxic effects on glioma cells in vitro. The drug uptake is assumed to depend on a specific estramustine binding protein (EMBP). One of the main difficulties in achieving cytotoxic effect in malignant brain tumours is believed to be due to the poor penetration of cytotoxic drugs into tumour tissue. In patients with malignant supratentorial brain tumours we have analysed the uptake of EMP metabolites in tumour tissue after oral administration and demonstrated EMBP in the same tissue specimens. Sixteen patients were given 280 mg EMP orally 14 h prior to surgery. Specimens from brain tumour tissue, cystic fluid, and serum were collected during surgery. Using gas chromatography the metabolites of EMP, estramustine (EaM) and estromustine (EoM), were quantified, EMBP was demonstrated by immunohistochemistry. The mean concentrations of EaM and EoM, expressed in ng g-1, were 60.3 and 38.4 in tumour tissue and 3.5 and 56.3 in serum, respectively. An accumulation of EaM in tumour tissue was found with a mean concentration gradient of 16.1 versus serum, while the gradient for EoM was 0.76. EMBP was demonstrated with a high degree of staining in all but one tumour. The high concentrations of EaM and EoM found in malignant brain tumour tissue correspond to potentially cytotoxic levels. The present results as well as the earlier in vitro demonstrated cytotoxic effects on glioma cells strengthen the possibility of a therapeutic effect of EMP in the treatment of malignant brain tumours.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bergenheim, A., Gunnarsson, P., Edman, K. et al. Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans. Br J Cancer 67, 358–361 (1993). https://doi.org/10.1038/bjc.1993.65
Issue Date:
DOI: https://doi.org/10.1038/bjc.1993.65
This article is cited by
-
Tissue concentration of systemically administered antineoplastic agents in human brain tumors
Journal of Neuro-Oncology (2011)
-
High-grade astrocytoma treated concomitantly with estramustine and radiotherapy
Journal of Neuro-Oncology (2006)
-
Effects of radiotherapy and estramustine on the microvasculature in malignant glioma
British Journal of Cancer (1999)
-
Targeting microtubule-associated proteins in glioblastoma: A new strategy for selective therapy
Annals of Surgical Oncology (1996)
-
Radiosensitizing effect of estramustine in malignant gliomain vitro andin vivo
Journal of Neuro-Oncology (1995)